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Abstract: Premature neonates often experience hyperglycaemia, which has been linked to increased 
mortality and worsened outcomes. Insulin therapy can assist in controlling blood glucose levels. However 
a reliable, robust control protocol is required to avoid hypoglycaemia and to meet nutrition goals. This 
study presents an adaptive, model-based predictive controller designed to incorporate the unique 
metabolic state and control parameters of the neonate. Controller performance was tested in virtual trials 
on a 25 patient retrospective cohort and 24-hour pilot clinical trials. The effects of measurement 
frequency and BG sensor error were also evaluated. Time in the 4 – 7 mmol/L BG band was increased by 
110%-145% compared to retrospective control for that cohort, with fewer hypoglycaemic measurements. 
Controllers were robust to BG sensor errors.  
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1. INTRODUCTION 
Premature infants commonly demonstrate poor glycaemic 
control. Up to 40%-80% of low birth weight infants 
experience hyperglycaemia during the neonatal period 
(Dweck and Cassady, 1974). Metabolic homeostasis in the 
preterm infant is often compromised by immaturity of control 
systems. Additionally, the metabolic response to stress is 
characterised by major changes in glucose metabolism 
(Ditzenberger et al., 1999). Increased secretion of counter-
regulatory hormones leads to a prominent rise in 
endogenously produced glucose and the rate of hepatic 
gluconeogenesis, as well as a reduction in insulin sensitivity. 
Inhibiting the physiological response to increased glycaemic 
levels are factors such as increased insulin resistance, 
absolute or relative insulin deficiency, and drug therapy. 
Hyperglycaemia is not only a marker for severity of illness, it 
also has been linked to worsened outcomes, leading to an 
increased risk of further complications, such as sepsis, 
retinopathy of prematurity and mortality (Van den Berghe et 
al., 2001, Ertl et al., 2006). High rates of proteolysis are also 
common in low birth weight infants, reducing muscle mass 
and inhibiting growth (Agus et al., 2004). 
Tight glucose control has been shown to reduce adult 
Intensive Care Unit (ICU) patient mortality by 45% (Van den 
Berghe et al., 2001). Prospective tight glucose control to a 
mortality and/or morbidity outcome has not yet been reported 
for the neonatal intensive care unit (NICU). 
Hyperglycaemia in preterm neonates is often treated by 
glucose restriction and/or the use of insulin infusions. Insulin 
infusions are gaining popularity amongst neonatologists, 
where they were once avoided due to the risk of 
hypoglycaemia and possible neurological sequelae. Limited 
trials of insulin infusions have been reported (Kairamkonda, 
2006). Positive outcomes of insulin infusion have been 
reduced proteolysis, improved glucose tolerance and 
improved weight gain. Negative reports of hypoglycaemia 
have also surfaced (Beardsall et al., 2008). 
Blood glucose control for the neonate poses several 
challenges that differ from the adult critical care case. Blood 
volumes in preterm infants are relatively small. Thus, the 
number of blood glucose measurements must be optimised to 
a minimum useful number to conserve volume and restrict 
opening incubator doors, which may affect the neonate’s 
hydration status. Endogenous energy substrates are very low 
in preterm infants at birth (Hume et al., 2005). Thus, these 
infants must be constantly fed to provide enough energy for 
basal requirements in addition to growth. In contrast, adults 
can tolerate periods of reduced caloric intake. Less saturation 
of the insulin-stimulated glucose uptake pathway has also 
been reported in neonates (Farrag et al., 1997) unlike in 
adults (Natali et al., 2000). Finally, also unlike the adult case, 
growth is a major goal of neonatal care. Thus, the anabolic 
effects of insulin are of relatively high importance (Agus et 
al., 2004). 
Great inter-patient heterogeneity in response to glucose and 
insulin infusions is a well-reported hallmark of neonatal 
glucose metabolism making safe, adequate control difficult 
(Cowett and Farrag, 2004). Thus, knowledge of the metabolic 
state of the infant is vital for optimal, safe blood glucose 
control using insulin. Model-based methods can provide 
information about the patient’s response to insulin based on 
serial blood glucose measurements, and insulin and nutrition 
data (Chase et al., 2006). This metabolic information can be 
combined with a controller utilising model predictions to 
achieve targeted blood glucose control. This approach has 
been validated in adult critical care studies (Chase et al., 
2006). However, sudden changes in patient condition 
independent of metabolic state indicate limits on model-based 
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controller actions are required to maximise safety and control 
performance. 
Therefore, there are several design parameters that must be 
considered in developing a safe, effective and optimal 
neonatal glycaemic control algorithm. Virtual trials offer the 
opportunity to explore control strategies in simulation before 
pilot clinical trials (Chase et al., 2007). The controller must 
account for inter-patient variability, nutritional inputs and 
varying physiological condition. Hence, it must be adaptive 
and/or able to identify changes in patient dynamics, 
particularly with respect to insulin sensitivity. The protocol 
should minimise labour and comply with existing medical 
protocols on the treatment of neonatal hyperglycaemia to 
ensure the method developed could be readily implemented 
in a clinical environment. Finally, the controller must be 
robust to sensor errors. 
2. METHODS 
2.1 System model 
The model is based on a clinically validated adult critical care 
glycaemic model, adapted to account for the main 
physiological differences in neonates.  
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Where G(t) [mmol/L] is the total plasma glucose and I(t) 
[mU/L] is the plasma insulin, exogenous insulin input is 
represented by uex(t) [mU/min] and basal endogenous insulin 
secretion IB [mU/L/min], with kI representing the suppression 
of basal insulin secretion in the presence of exogenous 
insulin. The effect of previously infused insulin being utilised 
over time is represented by Q(t) [mU/L], with k [1/min] 
accounting for the effective life of insulin in the system. 
Body weight and brain weight are denoted by mbody [kg] and 
mbrain [kg] respectively. Patient endogenous glucose clearance 
and insulin sensitivity are pG [1/min] and SI [L/(mU.min)], 
respectively. The parameter VI,frac [L/kg] is the insulin 
distribution volume per kilogram body weight and n [1/min] 
is the constant first order decay rate for insulin from plasma. 
Total plasma glucose input is denoted P(t) [mmol/min], 
endogenous glucose production is denoted by PEND 
[mmol/kg/min] and VG,frac [L/kg] represents the glucose 
distribution volume per kilogram of body weight. CNS 
[mmol/kg/min] represents non-insulin mediated glucose 
uptake by the central nervous system, as well as the liver, 
kidneys and red blood cells. Michaelis-Menten functions are 
used to model saturation, with αI [L/mU] used for the 
saturation of plasma insulin disappearance, and αG [L/mU] 
for the saturation of insulin-dependent glucose clearance.  
Table 1 summarises the parameters values. In this study, k, n, 
αI, αG, CNS, IB, VI,frac, pG and PEND are set to population 
values based on reported clinical neonate data. Prior clinical 
and model sensitivity studies (Hann et al., 2005) have shown 
this choice to be robust.  
Table 1. Model parameter values 
Parameter Value 
k 0.0086 min-1 
n 0.90 min-1 
αI 1.70 x 10-3 L/mU 
αG 0 L/mU 
CNS 0.088 mmol/kg/min 
mbrain 0.14 * mbody kg 
IB 12 mU/L/min 
VI,frac 0.045 L/kg 
VG,frac (Based on gestational age) L/kg 
PEND 0.02838 mmol/kg/min 
pG 0.003 min-1 
The insulin sensitivity parameter, SI, drives the dynamics of 
the blood glucose model and is assumed patient-specific and 
independent of exogenous insulin and nutrition 
administration. Once a patient-specific profile of time-
varying insulin sensitivity is generated, it can be used to 
predict blood glucose concentration based on different insulin 
and nutrition control schemes. Such analyses are effectively 
in-silico or virtual trials (Chase et al., 2007). 
2.2 Controller development 
The clinical implementation procedure for the controller is 
shown in Fig. 1. The blood glucose history, together with 
insulin and nutrition history, are used to fit the patient’s 
insulin sensitivity profile in real-time. This profile is then 
used by the controller to solve (1)-(3) to predict blood 
glucose concentration based on insulin and nutrition rates. 
Thus, the controller adapts to the current metabolic state of 
the neonate in real-time.  
 
 
Patient 
Identification: 
Fit insulin sensitivity. 
Forecast future insulin 
sensitivity. 
Control: 
Iterate possible insulin rates, 
solve model for each iteration, 
find closest match to target BG. 
Adjust insulin rate based on 
stochastic forecast if available. 
Controller 
recommendation 
Measurement: 
• Blood glucose (G(t)) 
Infusion data: 
• Insulin (u(t)) 
• Nutrition (P(t)) 
 
Fig. 1. Controller implementation schematic 
The controller uses a bisection algorithm to determine the 
insulin infusion rate that will bring the BG closest to a target 
BG, if the target is physiologically possible with safety. Thus, 
every BG measurement is followed by a controller 
intervention to alter the insulin infusion rate. The virtual trial 
procedure replaces the ‘Patient’ in Fig. 1 with a forward 
solution of the model using an insulin sensitivity profile 
generated from retrospective data, and adds sensor noise and 
other variations as required.  
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Crucially, blood volumes in neonates are small (Cassady, 
1966), which restricts the frequency of BG sampling, 
providing an additional challenge for model-based control in 
the neonatal setting. Thus, it is important to optimise the 
number of BG measurements required for control.  
Controllers using 1 – 4 hourly BG measurement and 
intervention intervals were examined and compared to 
retrospective hospital control and simulations using an 
insulin sliding scale as per standard care in Christchurch 
Women’s Neonatal Department, shown in Table 2.  
Table 2. Typical sliding scale for simulation. 
Blood glucose Insulin rate 
> 20 mmol/L 0.100 U/kg/hr 
15 – 20 mmol/L 0.075 U/kg/hr 
10 – 15 mmol/L 0.050 U/kg/hr 
5 – 10 mmol/L 0.025 U/kg/hr 
< 5 mmol/L STOP 
A BG measurement timing scheme based on current BG 
concentration was also tested. In particular, a high BG 
concentration carries little risk of hypoglycaemia and may 
thus require less frequent BG sampling compared to periods 
at lower concentrations. Hence, a BG-concentration derived 
measurement scheme was simulated where measurements 
were taken every 3 hours if BG > 8 mmol/L and any decrease 
in BG since the last measurement was less than 2 mmol/L/hr. 
Measurements were taken 2-hourly if BG was within the 4-8 
mmol/L range, and hourly otherwise up to a limit of 12 
measurements per day. Unless otherwise stated, all  
simulations were performed with uniformly distributed 7% 
measurement error (Chen et al., 2003). 
The metabolic status of a critically ill neonatal patient can 
change rapidly. This change is reflected by sudden rises and 
drops in insulin sensitivity. Additionally, sudden changes in 
apparent insulin sensitivity may be caused by sensor noise 
and/or measurement error (Chase et al., 2007). Thus, a 
balance is required between the speed at which a controller 
reacts to correct blood glucose rises due to sudden changes in 
metabolic state, and the risk of running higher insulin 
infusion rates when a sudden rise in blood glucose resolves 
quickly, or was due to measurement error. A maximum 
insulin infusion rate of 0.5 U/kg/hr and peak increase of 0.03 
U/kg/hr per intervention were used in the model-based 
controller. 
Finally, the effect of BG sensor error was explored in 
simulated trials by adjusting the amount of uniformly 
distributed noise added to simulated BG measurements. 
Values of 2%, 5%, 10%, 15% and 20%, represent the range 
(and beyond) seen in clinical practice depending on the BG 
sensor/analyser used (Chen et al., 2003). 
2.3 Patient cohort 
Retrospective data for 25 episodes of insulin usage over 21 
patients from the Christchurch Women’s Neonatal Intensive 
Care Unit was used in the study. Ethics approval for the 
collection and publication of data was obtained from the 
Upper South Regional Ethics Committee. Median gestational 
age at birth was 26.6 weeks, and median birth weight was 
0.845 kg. Inclusion criteria were a period of treatment with 
insulin and at least six blood glucose measurements per day. 
Hourly-varying insulin sensitivity was fitted to each of the 25 
patient profiles to generate a cohort of 25 ‘virtual patients’ 
used for simulation. 
Two 24-hour pilot clinical trials of the model-based 
controller are presented. The two subjects were born at 
27.3wks and 25.4wks gestational age and birth weight 0.77 
kg and 0.72 kg respectively. The trials were conducted at age 
9 days and 2 days respectively. 
3. RESULTS 
Table 3 compares blood glucose performance metrics and 
insulin intake for clinical retrospective NICU control, 
simulated sliding scale, and targeted control. The blood 
glucose target is 6.0 mmol/L or a 15% reduction per hour 
from the current BG concentration, whichever is the greater 
value. The median BG for all model-based control cases is at, 
or close, to the target BG. The percentage of measurements 
within the 4 – 7 mmol/L and 4 – 8 mmol/L ranges are [110% 
- 145%] and [65% - 87%] higher than retrospective hospital 
control, respectively. The sliding scale had higher median BG 
than either model-based control or retrospective results. A 
sample model fit to the data simulation of a sliding scale 
controller is presented in Fig. 2. 
Table 3. Simulated control results and retrospective data.  
 Model-based controller 
 2hr 3hr 4hr 
Total measurements 1771 1175 879 
Median BG (mmol/L) 6.0 6.0 6.1 
BG IQRa (mmol/L) [5.4-6.8] 
[5.3-
7.0] 
[5.2-
7.2] 
% within 4-7 mmol/L 76% 69% 65% 
< 2.6 mmol/L 0.45% 0.60% 0.91% 
Insulin intake (U/kg/hr) 0.056 0.057 0.055 
 Sliding scale 
 2hr 4hr Retro. 
Total measurements 1771 879 1091 
Median BG (mmol/L) 8.6 8.5 8.0 
BG IQRa (mmol/L) [6.9-10.5] 
[6.9-
10.8] 
[6.3-
9.9] 
% within 4-7 mmol/L 25% 24% 31% 
< 2.6 mmol/L 0.34% 0.57% 0.73% 
Insulin intake (U/kg/hr) 0.029 0.030 0.034 
aIQR, Inter-Quartile Range. 
The length of time between blood glucose measurements 
reduces the quality of model-based control, dropping from 
76% to 65% of BG measurements within the 4 – 7 mmol/L 
band for 2-hour to 4-hour measurement intervals. The 
proportion of simulated measurements below 2.6 mmol/L is 
less than retrospective control for 2-hourly and 3-hourly 
measurements, but slightly greater for 4-hourly 
measurements. The IQR width for retrospective control was 
3.6 mmol/L, and 3.6 – 3.9 mmol/L for sliding scale control. It 
was 1.4 – 2.2 mmol/L for model-based control. Sliding scale 
control results were similar across measurement frequencies. 
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Insulin usage across measurement frequencies was similar for 
model-based control, and 65% - 74% higher than hospital 
control. The highest proportion of measurements within the 
target band was for the 2-hour control. 
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Fig. 2. Model fit through BG data and control simulation. 
Fig. 3 shows the median patient cumulative distribution 
function (CDF) and 5% - 95% range of CDFs of the per-
patient control results for the model-based controller with 2-
hour measurements, and retrospective data. The inter-patient 
variation in BG control with the model-based controller is far 
tighter than the retrospective control. Thus, the model-based 
controller better modulates insulin to account for each 
individual patient’s glycaemic response. 
 
Fig. 3. Median and 5%-95% CDF of BG for simulated 
model-based control and retrospective data. 
All model-based controller results are significantly different 
from the retrospective BG measurement distribution (p < 
0.05). It is important to note the curves presented in Fig. 3 are 
not symmetrical – the slope at lower BG ranges is steeper, 
thus BG results when not within the target range are skewed 
towards the upper BG range, as mild hyperglycaemia is 
considered safer than an increased risk of hypoglycaemia.  
Fig. 4 compares the proportion of BG measurements within 
the target 4 – 7 mmol/L band for retrospective and model-
based control. Only one patient retrospectively had greater 
than 50% of BG measurements within the target band under 
hospital control. All patients had greater than 50% of BG 
measurements within the target band with model-based 
control. The 45º line in Fig. 4 represents the line of no-
change in performance. The distance from the line is a 
measure of the increase in BG measurements within the 
target band per-patient. 
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Fig. 4. Retrospective measurements within target BG range 
compared to model-based controller virtual trials. 
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Fig. 5. Effect of simulated BG sensor error on BG control. 
Fig. 5 compares glycaemic control performance with 
different measurement errors for different intervals. Most 
accurate control was achieved with the minimum 
measurement noise, as expected. Decreases in time in 
glycaemic control bands showed a similar pattern for all 
measurement frequencies.  
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Fig. 6. Measurements within target BG range compared to 
number of measurements. 
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The BG concentration-based variable measurement frequency 
scheme resulted in lower time in target BG band, higher 
median BG and wider BG inter-quartile range. This result is 
emphasised in Fig. 6, which compares the percentage of BG 
measurements with the target band against total simulated 
BG measurements for several BG measurement schemes. The 
retrospective and BG-concentration based measurement 
frequency results are below a linear line through the constant 
measurement frequency results. Thus, these measurement 
frequency schemes do not make a more optimal use of the 
measurements available compared to the clinically easier 
regular measurement frequency. 
Fig. 7 and Fig. 8 present two 24-hour clinical control trials. In 
both cases blood glucose concentration is reduced in a 
controlled manner to the target 4 – 7 mmol/L band. BG 
prediction accuracy was 9.8% and 8.8% for Trials 1 and 2 
respectively. Insulin sensitivity for Trial 2 was much lower 
than Trial 1, providing a broad indication of severity of 
illness and ability of insulin to maintain tight control. Up to 
60% of dextrose calories in Trial 2 were administered via 
morphine and dobutamine solutions, in addition to parenteral 
nutrition. Controller BG concentration targets for Trial 2 
aimed for a 15% reduction in glycaemia to achieve a steady, 
controlled descent in glucose levels to the target range. 
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Fig. 7. NICU clinical control Trial #1. The shaded area in the 
top panel represents BG forecast bounds, and the circle 
represents the target BG concentration. 
 
4. DISCUSSION 
Hyperglycaemia has been recently linked to poor outcomes 
for premature infants. However, there is currently no set 
protocol or best-practice method available. The success of 
model-based and model-derived control in limited trials in 
adult intensive care patients (Chase et al., 2007, Chase et al., 
2008) suggest that model-based methods could be useful for 
metabolic management in neonates.  
This study shows that time in a relevant glycaemic band is a 
clearer indication of control performance when comparing 
control protocols than a median value. The median blood 
glucose did not change significantly. However, time in band 
decreased dramatically in the presence of long measurement 
intervals out to 4 hours, indicating increased glycaemic 
variability and thus potentially worse outcomes (Egi et al., 
2006). The BG IQR width reflected these changes in BG 
variability. However, time in band provides and easy-to-
visualise method of comparison. Finally, cumulative 
distribution functions provide both a direct comparison and 
time in any desired glycaemic band. 
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Fig. 8. NICU clinical control Trial #2. 
Pump flow rates in neonatal intensive care are very low given 
the very small doses. Pump accuracy can affect the quality of 
control, as well as insulin adsorption to pump tubing (Fuloria 
et al., 1998). This effect can be minimised by either adding 
albumin to the insulin mixture, or flushing the infusion pump 
tubing with insulin solution prior to use. Christchurch 
Women’s hospital flushes all insulin tubing to minimise 
adsorption effects (Fuloria et al., 1998). Thus, this effect is 
not evident in the clinical data used. 
The ideal range for blood glucose concentration in neonatal 
intensive care is under debate (Cowett and Farrag, 2004). 
Unlike adults, a major proportion of energy for brain 
metabolism is provided by fuels other than glucose (eg: 
ketones). Thus, the neonatal brain may be more resistant to 
hypoglycaemia compared to the adult. However, persistent 
low blood glucose concentration (< 2.6 mmol/L) can reduce 
cerebral development and lead to long term neurological 
deficiencies (Lucas et al., 1988). For this study, the 4 – 7 
mmol/L range was targeted, similar to several adult studies. 
However, to date, no outcome based study has provided a 
specific insight or result in this regard. 
A paper-based protocol (SPRINT) developed from a similar 
model has been used on 394 adult intensive care patients 
(Chase et al., 2008). SPRINT uses 1-2 hourly measurements, 
and modulates both insulin and nutrition to achieve tight 
glycaemic control. It achieved 79% of measurements in a 
target 4 – 7 mmol/L band, which is similar to the 76% in 
these virtual trials within same band using a 2-hour 
measurement frequency. The added nutrition modulation 
provides another pathway for BG reduction that can be 
effective during periods of very low insulin sensitivity, 
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particularly as adults appear to exhibit greater insulin effect 
saturation than preterm neonates. In contrast, extremely 
preterm infants lack substantial endogenous stores of energy, 
and thus must be fed constantly to maintain basal energy 
expenditure and provide excess for growth (Hume et al., 
2005). Therefore, any similar system for neonates would 
likely be an “insulin-only” controller or one that sought to 
maximise nutritional inputs. 
Further improvements to the model could incorporate daily 
nutritional and volume goals that can be set by clinicians with 
model-based targeted control taking care of glycaemia – thus 
relieving clinical staff from estimation and ad-hoc decision 
making. The ideal content and composition of nutritional 
regimes for preterm infants is still under debate. The 
proportions of dextrose, protein and lipids given in the NICU 
may be different to what an infant receives in-utero. Whilst 
the relevant major organs express many of the biological 
mechanisms responsible for glucose regulation from a 
relatively early age, the foetus depends upon the mother to 
control energy supply. Thus, the controller is essentially 
attempting to replicate some of the mother’s functions, as 
well as account for the synchronised processes that regulate 
foetal growth that are perturbed by premature birth and life 
outside the womb. 
5. CONCLUSIONS 
A model of the neonatal glucose regulatory system is adapted 
from adult critical care. Simulated trials revealed the 
sensitivity of control performance to frequency of BG 
measurement. Optimised control schemes improved 
glycaemic control in simulation versus hospital control over a 
range of patients. Model and controller performance were 
validated in pilot clinical trials. 
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